169 related articles for article (PubMed ID: 32067262)
1. First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.
Kaufmann P; Ort M; Golor G; Kornberger R; Dingemanse J
Br J Clin Pharmacol; 2020 Jul; 86(7):1377-1386. PubMed ID: 32067262
[TBL] [Abstract][Full Text] [Related]
2. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313.
Kaufmann P; Ort M; Golor G; Kornberger R; Dingemanse J
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110166. PubMed ID: 33159976
[TBL] [Abstract][Full Text] [Related]
3. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
Richard M; Kaufmann P; Kornberger R; Dingemanse J
Epilepsia; 2019 May; 60(5):968-978. PubMed ID: 31004346
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
5. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
6. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
[TBL] [Abstract][Full Text] [Related]
7. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
11. Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a
Anliker-Ort M; Dingemanse J; Farine H; Groenen P; Kornberger R; van den Anker J; Kaufmann P
Br J Clin Pharmacol; 2023 Jan; 89(1):380-389. PubMed ID: 36000981
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.
Yang L; Shu P; Wu N; Hu M; Luo Z
Eur J Pharm Sci; 2023 Oct; 189():106552. PubMed ID: 37532064
[TBL] [Abstract][Full Text] [Related]
13. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.
Muehlan C; Brooks S; Zuiker R; van Gerven J; Dingemanse J
Eur Neuropsychopharmacol; 2019 Jul; 29(7):847-857. PubMed ID: 31221502
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers.
Brooks S; Zuiker R; Bleys C; Ziagkos D; Moyer JA; van Nueten L; Bonaventure P; Drevets WC; van Gerven J; Salvadore G; Jacobs GE
J Psychopharmacol; 2023 Jun; 37(6):577-589. PubMed ID: 37165642
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.
Muehlan C; Boehler M; Brooks S; Zuiker R; van Gerven J; Dingemanse J
J Psychopharmacol; 2020 Mar; 34(3):326-335. PubMed ID: 31642731
[TBL] [Abstract][Full Text] [Related]
16. First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.
Klein S; Gashaw I; Baumann S; Chang X; Hummel T; Thuß U; Friedrich C
Br J Clin Pharmacol; 2022 Oct; 88(10):4552-4564. PubMed ID: 35437837
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
Boof ML; Géhin M; Voors-Pette C; Hsin CH; Sippel V; Strasser DS; Dingemanse J
Br J Clin Pharmacol; 2024 Feb; 90(2):588-599. PubMed ID: 37752659
[TBL] [Abstract][Full Text] [Related]
19. First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients.
Ort M; Dingemanse J; Hsin CH; Richard M; Huehn E; Sabattini G; van de Wetering J; Kornberger R; van den Anker J; Kaufmann P
Basic Clin Pharmacol Toxicol; 2022 Aug; 131(2):114-128. PubMed ID: 35596117
[TBL] [Abstract][Full Text] [Related]
20. A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
Fossler MJ; Schmith V; Greene SA; Lohmer L; Kramer MS; Arscott K; James IE; Demitrack MA
CNS Drugs; 2020 Aug; 34(8):853-865. PubMed ID: 32676977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
